RJ
Therapeutic Areas
Fulcrum Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Losmapimod | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 |
| Pociredir (FTX-6052) | Sickle Cell Disease (SCD) | Phase 1b |
| FTX-6052 | Beta-thalassemia | Discovery |
| FTX-273 | Diamond Blackfan Anemia / Bone Marrow Failure Syndromes | Discovery |
Leadership Team at Fulcrum Therapeutics
BE
Bryan E. Stuart
President and Chief Executive Officer
JA
Judith A. Dunn, Ph.D.
President of Research and Development
ER
Esther Rajavelu
Chief Financial Officer
CM
Chris Moxham, Ph.D.
Chief Scientific Officer
SN
Sara Nochur, Ph.D.
Chief Regulatory and Quality Officer